T-NK Cell Lymphoma
Conditions
Keywords
PET/CT, Granzyme B, immunotherapy
Brief summary
The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.
Detailed description
The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 68Ga-grazytracer PET at baseline and after one course of immunotherapy.
Interventions
None listed
Sponsors
Ruijin Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age \> 18 years, regardless of gender. 2. Histopathologically confirmed diagnosis of T-NK cell lymphoma. 3. Newly diagnosed and untreated patients or refractory/relapsed patients preparing to undergo immunotherapy. 4. Availability of complete clinicopathological and follow-up data. 5. Signed and dated informed consent form.
Exclusion criteria
1. Patients who have previously received anti-tumor therapy. 2. Patients with a history of other malignancies. 3. Incomplete clinical information or imaging data. 4. Concurrent other malignant tumors. 5. Patients with severe medical conditions deemed unsuitable for participation in this clinical study by the investigator, such as severe cardiopulmonary insufficiency or severe hepatic and renal dysfunction. 6. Poor compliance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Standardized uptake value (SUV) | Baseline and 7-10 days after treatment | SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progress free suivival | 3 years | Progress free suivival |
| Overall survival | 3 years | Overall survival |
Countries
China
Contacts
Primary ContactXinyu Zhang
Outcome results
None listed